Diagnose Breast Cancer Articles & Analysis
31 news found
Cirdan are delighted to announce that together with Queen’s University Belfast and our KTP Associate and Senior AI Engineer, Jonathan Armstrong, we have been selected as the winners of the Best KTP project by Innovate UK. Innovate UK’s Best Knowledge Transfer Partnership award honours the KTP which has brought the greatest benefits to all three participants, exceeding the expectations ...
October marks a month dedicated to a cause close to the core of everything which we do at Cirdan: Breast Cancer Awareness. This month will see a surge in activism surrounding breast cancer awareness and a push for finding a cure from around the globe. The fight to treat and cure breast cancer continues constantly, and we pride ourselves in taking part in the fight to save lives. Breast cancer ...
Cirdan are delighted to announce that together with Queen’s University Belfast and our KTP Associate and Senior AI Engineer, Jonathan Armstrong, we have been shortlisted for Innovate UK’s esteemed Best Knowledge Transfer Partnership Award. Innovate UK’s Best Knowledge Transfer Partnership award honours the KTP which has brought the greatest benefits to all three participants, ...
Prelude Corporation (PreludeDx, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced compelling results in 926 women diagnosed with ductal carcinoma in situ (DCIS). ...
Prelude Corporation (PreludeDx, a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that its study in 926 DCIS patients demonstrating the clinical utility of DCISionRT? ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced compelling results in 926 women diagnosed with ductal carcinoma in situ (DCIS). ...
Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. ...
Seno Medical Instruments, Inc. (Seno Medical), a Texas-based medical imaging company developing breakthrough breast cancer diagnostic technology, announced an educational partnership supporting Worldwide Breast Cancer’s “Know Your Lemons” campaign starting with the Netherlands, which has one of the highest breast cancer incidence rates in the world. Through the partnership with ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will be presenting data comparing DCISionRT? ...
Following the success of the world's leading AI Breast Care system, Transpara®, now in use across the US and in 30 countries worldwide, ScreenPoint Medical, the company that developed Transpara, has appointed Mark Koeniguer as its new CEO to lead the next phase of growth and accelerate the company's international expansion. Koeniguer, who has extensive experience leading and growing ...
Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced the publication of SweDCIS randomized clinical trial data in the Special Issue: Updates on Breast Cancer edition of Cancers. ...
” RSViP works by analyzing images from each woman’s prior screening and assessing each case based on AI-detected signals of suspected lesions and the potential to develop breast cancer using machine learning insights. With an unbiased assessment for every unscreened woman, RSViP generates an actionable list that the breast screening ...
Aidoc’s comprehensive AI continues to expand to cover the majority of radiology adult subspecialties Aidoc, the leading provider of AI for medical imaging, and ScreenPoint Medical, leader of deep learning AI for 2D and 3D mammography, today announced a collaboration which will incorporate ScreenPoint’s capabilities into Aidoc’s platform. Breast imaging specialists will now be ...
ByAidoc
Our team is absolutely elated that such an opportunity was presented to us so that we could advance state-of-the-art breast healthcare in Nigeria and across Africa!” Breast cancer surpassed lung cancer in 2020 as the most frequently diagnosed cancer in the world with 2.3 million newly ...
“We are excited to announce the advancement of our regulatory strategy for the IceSense3 system in China, as we look to bring our minimally-invasive therapy to more cancer patients around the world. With more than 400,000 new breast cancer cases diagnosed in China in 2020, according to the World Health Organization, ...
“It goes to show how excited people are about our mission and demonstrates people’s desire to help millions of women around the world avoid later-stage breast cancer diagnoses.” The company aims to raise a maximum of $5M via Republic. ...
Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. ...
Improving the speed of the diagnostic process supports the initiation of primary treatment at the earliest possible opportunity.” The breast cancer investigations conducted so far at the University of Leeds using the 4D Q-plasia OncoReader Breast platform have focused on identifying the presence of breast ...
The Center for Devices and Radiological Health (CDRH) of the US Food & Drug Administration (FDA) has granted Texas-based Seno Medical Instruments, Inc. (Seno) premarket approval (PMA) for its groundbreaking diagnostic breast cancer imaging technology that helps physicians better differentiate between benign and malignant breast lesions. The company’s Imagio® Breast Imaging System ...
An artificial intelligence (AI)-based breast ultrasound software from Koios Medical, Inc. proven to significantly enhance the accuracy and consistency of lesion assessment for physicians across a wide range of experience levels, per a study recently published in the American Journal of Roentgenology, is now being used to diagnose breast ...